Using novel high throughput genome engineering and screening technologies in a design loop with computational tools, 64x Bio is developing new ways of generating highly optimized and otherwise unattainable cell lines for the manufacturing of viral vectors, with a specific focus on those used for cell and gene therapies. The novel approach developed by founders at Harvard Medical School and the Wyss Institute at Harvard University promises to bring more cell and gene therapies to patients.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
01/20/22	$55,000,000	Series A	Alix Ventures BoxGroup Chris Gibson Fifty Years First Round Capital Future Ventures LifeForce Capital Michael Chambers Northpond Ventures Refactor Capital SV Angel	undisclosed